DMXD-011
/ Domainex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 15, 2022
Domainex nominates DMXD-011 as preclinical drug candidate for interferonopathies
(Bioworld)
- "Following a research program to identify inhibitors of protein kinases TBK1 and IKK-ε, Domainex Ltd. has nominated DMXD-011 as a preclinical drug candidate."
Pipeline update • Interferonopathies
1 to 1
Of
1
Go to page
1